These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15221011)

  • 1. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
    Luwor RB; Zhu HJ; Walker F; Vitali AA; Perera RM; Burgess AW; Scott AM; Johns TG
    Oncogene; 2004 Aug; 23(36):6095-104. PubMed ID: 15221011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel EGF-sensitive cell cycle checkpoint.
    Walker F; Zhang HH; Burgess AW
    Exp Cell Res; 2007 Feb; 313(3):511-26. PubMed ID: 17157295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
    Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
    Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation.
    Pedersen MW; Pedersen N; Damstrup L; Villingshøj M; Sønder SU; Rieneck K; Bovin LF; Spang-Thomsen M; Poulsen HS
    J Cell Biochem; 2005 Oct; 96(2):412-27. PubMed ID: 16075456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
    Amann J; Kalyankrishna S; Massion PP; Ohm JE; Girard L; Shigematsu H; Peyton M; Juroske D; Huang Y; Stuart Salmon J; Kim YH; Pollack JR; Yanagisawa K; Gazdar A; Minna JD; Kurie JM; Carbone DP
    Cancer Res; 2005 Jan; 65(1):226-35. PubMed ID: 15665299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
    Bremm A; Walch A; Fuchs M; Mages J; Duyster J; Keller G; Hermannstädter C; Becker KF; Rauser S; Langer R; von Weyhern CH; Höfler H; Luber B
    Cancer Res; 2008 Feb; 68(3):707-14. PubMed ID: 18245470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma.
    Fenstermaker RA; Ciesielski MJ
    Oncogene; 2000 Sep; 19(39):4542-8. PubMed ID: 11002427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N; De Luca A; Bianco C; Strizzi L; Mancino M; Maiello MR; Carotenuto A; De Feo G; Caponigro F; Salomon DS
    Gene; 2006 Jan; 366(1):2-16. PubMed ID: 16377102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
    Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
    FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.